Leukemia and Lymphoma

Chimeric antigen receptor (CAR) T cells can be highly effective, but the durability of the therapy has been lacking in many patients with hematological malignancies. Many efforts are underway to fix this problem.

In what is believed to be the first study of its kind, investigators found patients with leukemia face a higher risk of suicide than the general public, especially if they had acute myeloid leukemia.

Many patients with acute lymphoblastic leukemia (ALL) who undergo chemotherapy end up back in the hospital within 30 days. A new study points out the reasons and opportunities for prevention.

Immune-associated neurotoxicity in patients following chimeric antigen receptor (CAR) T-cell therapy may be due to monocyte-like cells in infusion products, explained Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.

Previous research has found a link between a prior malignancy and secondary primary malignancy risk in patients with multiple myeloma. A new study suggests a similar association in follicular lymphoma.

A 72-year-old patient with Burkitt lymphoma was successfully treated with nivolumab after standard-of-care chemotherapy failed.

Chimeric antigen receptor (CAR) T-cell therapy does not always lead to a durable response, and we are trying to figure out why, noted Michael R. Green, PhD, University of Texas MD Anderson Cancer Center.

T-cell prolymphocytic leukemia is rare and shares many features with other conditions. A new review article helps explain some of the tactics physicians can use to correctly identify it.

It is the first PD-1 inhibitor to be approved to be used as a monotherapy for the treatment of adult and pediatric patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL).

Based on the findings, the researchers are arguing that minimal residual disease (MRD) should be considered as a clinical trial endpoint.

The process of approving a new therapy for relapsing and/or remitting mantle cell lymphoma therapy got off to a faster start in China, but United States regulators caught up and approved the drug first.

A patient with chronic lymphocytic leukemia (CLL) was continued on ibrutinib even after developing severe coronavirus disease 2019 (COVID-19). He successfully overcame the infection.

Research into children and adolescents with nonremission acute lymphoblastic leukemia (ALL) has been sparse, but a new analysis suggests that allogeneic hematopoietic stem cell transplantation is a good fit for some patients.

Patients with acute lymphoblastic leukemia (ALL) who have an ABL-class fusion had better outcomes than a control group when treated with tyrosine kinase inhibitors at their first relapse, according to a new study.

A new chimeric antigen receptor (CAR) T cell therapy may help curb the problem of frequent relapse in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Ibrutinib can lead to side effects, causing some physicians to consider reducing the dose or temporarily halting therapy, but that risks disease flares, a new study finds.

Patients with chronic lymphocytic leukemia (CLL) have worse health-related quality of life scores compared to healthy controls, according to a new study out of India.

New research casts doubt on the notion that hepatitis plays a role in the development of multiple myeloma (MM), finding that the virus is actually more common in chronic lymphocytic leukemia (CLL).

A significant number of patients who undergo chimeric antigen receptor (CAR) T-cell therapy will experience severe neurotoxicity. A new study could help doctors better predict which patients are at risk.

Mantle cell lymphoma is considered incurable, but a new strategy could lead to better results in a subgroup of patients with the cancer.

Patients who are diagnosed with Waldenström macroglobulinemia (WM) at age 55 or younger tend to have low risk profiles and very high overall survival rates.

Children receiving intensive chemotherapy benefit from prophylaxis with levofloxacin to an extent that would justify the cost of the drug, a new analysis finds.

Reporting on their findings in the British Journal of Haematology, researchers have used immunohistochemistry (IHC) to leverage p53 expression as an identifier of mantle cell lymphoma (MCL) patients carrying mutations in tumor protein p53 (TP53), an indicator of poor prognosis in the disease.

Fewer off-target effects mean second-generation BTK inhibitors offer less cardiotoxicity and allow patients to stay on them longer, increasing their efficacy.

Patients with chronic lymphocytic leukemia (CLL) often face months or years of uncertainty. A new study might help those patients better understand their progression timeline.

A significant proportion of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) experience bleeding when taking ibrutinib—a recent study probes why.

Tisagenlecleucel, sold as Kymriah by Novartis, met its primary end point of complete response rate (CRR) in an interim analysis of a phase 2 study for relapsed or refractory follicular lymphoma (FL).

Understanding the patient point of view can help with treatment decisions as well as gauge the impact of treatment, the authors said.

While immunoglobulin abnormalities appear to shorten treatment-free survival periods, they do not have an impact on overall survival in patients with chronic lymphocytic leukemia (CLL).

The therapy, to be sold as Tecartus, will be used to treat adult patients with mantle cell lymphoma who have relapsed or not responded to other treatments.